Epigenetic targets in the diagnosis and treatment of prostate cancer

International Braz J Urol

Volumn 33, Issue 1, 2007, Pages 11-18

  Manoharan, Murugesan ^a,b   Ramachandran, Kavitha ^b   Soloway, Mark S ^a,b   Singal, Rakesh ^b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

DNA methylation; Epigenesis; Genetic; Prostate cancer

Indexed keywords

EID: 33947405248     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382007000100003     Document Type: Review

References (43)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, et al.: Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10-30. Erratum in: CA Cancer J Clin. 2005; 55: 259.
2. Wolffe AP, Matzke MA: Epigenetics: regulation through repression. Science. 1999; 286: 481-6.
3. Crawford ED: Epidemiology of prostate cancer. Urology. 2003; 62: 3-12.
4. Smith RA, Cokkinides V, Eyre HJ: American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003; 53: 27-43.
5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-46. Erratum in: N Engl J Med. 2004; 351: 1470.
6. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004; 172: 1297-301.
7. Singal R, Ferdinand L, Reis IM, Schlesselman JJ: Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004; 12: 631-7.
8. Das PM, Singal R: DNA methylation and cancer. J Clin Oncol. 2004; 22: 4632-42.
9. Li LC, Carroll PR, Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005; 97: 103-15.
10. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429: 457-63.
11. Rodenhiser D, Mann M: Epigenetics and human disease: translating basic biology into clinical applications. CMAJ. 2006; 174: 341-8.
12. Peterson CL, Laniel MA: Histones and histone modifications. Curr Biol. 2004; 14: R546-51.
13. Rountree MR, Bachman KE, Herman JG, Baylin SB: DNA methylation, chromatin inheritance, and cancer. Oncogene. 2001; 20: 3156-65.
14. Li LC, Okino ST, Dahiya R: DNA methylation in prostate cancer. Biochim Biophys Acta. 2004; 1704: 87-102.
15. Robertson KD: DNA methylation and chromatin - unraveling the tangled web. Oncogene. 2002; 21:5361-79.
16. Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD, et al.: Protection against 2-hydroxyamino-l-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 2001; 61: 103-9.
17. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada, K: DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn J Cancer Res. 2002; 93: 767-73.
18. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, et al.: Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006; 66: 2562-9.
19. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, et al.: The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol. 2004; 6: 129-37.
20. Sekita N, Suzuki H, Ichikawa T, Kito H, Akakura K, Igarashi T, et al.: Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn J Cancer Res. 2001; 92: 947-51.
21. Schmitt JF, Millar DS, Pedersen JS, Clark SL, Venter DJ, Frydenberg M, et al.: Hypermethylation of the inhibin alpha-subunit gene in prostate carcinoma. Mol Endocrinol. 2002; 16: 213-20.
22. Chen H, Toyooka S, Gazdar AF, Hsieh JT: Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem. 2003; 278: 3121-30.
23. Bedford MT, van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 1987; 47: 5274-6.
24. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M: A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 1999; 397: 579-83.
25. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997; 389: 251-60.
26. Jenuwein T, Allis CD: Translating the histone code. Science. 2001; 293: 1074-80.
27. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI: Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 1999; 59: 2981-8.
28. Tsubaki J, Hwa V, Twigg SM, Rosenfeld RG: Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. Endocrinology. 2002; 143: 1778-88.
29. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, et al.: Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002; 62: 3812-8.
30. Moggs JG, Goodman JI, Trosko JE, Roberts RA: Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol. 2004; 196: 422-30.
31. Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, et al.: The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest. 2001; 81: 1049-57.
32. Miyamoto K, Ushijima T: Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol. 2005; 35: 293-301.
33. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, et al.: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000; 60: 5941-5.
34. Harden SV, Guo Z, Epstein JI, Sidransky D: Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003; 169: 1138-42.
35. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D: Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res. 2004; 10: 5518-22.
36. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al.: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004; 64: 1975-86.
37. Kollermann J, Muller M, Goessl C, Krause H, Helpap B, Pantel K, et al.: Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur Urol. 2003; 44: 533-8.
38. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst. 2003; 95: 661-8.
39. Christman JK: 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002; 21: 5483-95.
40. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al.: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103: 1635-40.
41. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol. 2004; 24: 1270-8.
42. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al.: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000: 60: 5165-70.
43. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, et al.: Sodium butytrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004; 90: 535-41.